TY  - JOUR
A1  - Davila, Mariela Martinez
A1  - Papada, Efstathia
KW  - phytochemicals; inflammatory bowel disease; gut microbiota; Mastiha; Curcumin; Boswellia serrata; Artemisia absinthium
JF  - Life
PB  - MDPI AG
UR  - https://doi.org/10.3390/life13081703
N2  - Inflammatory bowel diseases (IBD), including Crohn?s disease (CD) and ulcerative colitis (UC), are a major healthcare challenge worldwide. Disturbances in the immune system and gut microbiota followed by environmental triggers are thought to be part of the aetiological factors. Current treatment for IBD includes corticosteroids, immunosuppressants, and other biologic agents; however, some patients are still unresponsive, and these are also linked to high financial load and severe side effects. Plant-derived natural products are rich in phytochemicals and have been used as healing agents in several diseases since antiquity due to their antioxidant, anti-inflammatory, and immunomodulatory properties, as well as gut microbiota modulation. Numerous in vitro and in vivo studies have shown that phytochemicals act in key pathways that are associated with the pathogenesis of IBD. It is also reported that the use of plant-derived natural products as complementary treatments is increasing amongst patients with IBD to avoid the side effects accompanying standard medical treatment. This review summarises the relevant evidence around the use of plant-derived natural products in the management of IBD, with specific focus on the clinical evidence so far for Curcumin, Mastiha, Boswellia serrata, and Artemisia absinthium.
ID  - discovery10175363
IS  - 8
N1  - © 2023 by the Authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
AV  - public
Y1  - 2023/08//
VL  - 13
TI  - The Role of Plant-Derived Natural Products in the Management of Inflammatory Bowel Disease?What Is the Clinical Evidence So Far?
ER  -